Patents by Inventor Anthony Howard Ingall
Anthony Howard Ingall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080207642Abstract: The invention relates to a compound of formula (1): in which R1 and R2 each independently represent a C1-6alkyl, C3-6alkenyl, C3-6cycloalkylC1-3alkyl or C3-6cycloalkyl; each of which is optionally substituted by 1 to 3 halogen atoms; R3 is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is —CO— or —C(R4)(R5)— in which R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group; and Ar is a 5- to 10-membered aromatic ring system in which up to 4 ring atoms may be heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.Type: ApplicationFiled: April 29, 2008Publication date: August 28, 2008Inventors: Rachel Heulwen Reynolds, Anthony Howard Ingall, Rukhsana Tasneem Rasul, Simon David Guile, Martin Edward Cooper
-
Patent number: 7393854Abstract: The invention relates to thienopyrimidinediones of formula (I): wherein: R1, R2, Q are as defined in the specification, and Ar and Ar2 are selected from certain aromatic ring systems which may be optionally substituted, as defined in the specification. Processes for the preparation of compounds of formula (I), pharmaceutical compositions containing them and their use in therapy are also described and claimed.Type: GrantFiled: January 15, 2004Date of Patent: July 1, 2008Assignee: AstraZeneca ABInventors: Simon David Guile, Anthony Howard Ingall
-
Publication number: 20080153855Abstract: The invention relates to a compound of formula (1) in which Q is —CO— or —C(R4)(R5)—, where R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group; and Ar is a 5- to 10-membered aromatic ring system where up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.Type: ApplicationFiled: February 28, 2008Publication date: June 26, 2008Inventors: Rachel Heulwen Reynolds, Anthony Howard Ingall
-
Patent number: 7384950Abstract: The invention relates to a compound of formula (1); wherein: R1 and R2 each independently represent a C1-6alkyl, C3-6 alkenyl, C3-6 cycloalkyl C1-3 alkyl or C3-6 cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R3 is isoxyzolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is CO— or C(R4)(R5)-(wherein R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group); Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification.Type: GrantFiled: July 24, 2002Date of Patent: June 10, 2008Assignee: AstraZeneca ABInventors: Rachel Heulwen Reynolds, Anthony Howard Ingall, Rukhsana Tasneem Rasul, Simon David Guile, Martin Edward Cooper
-
Patent number: 7361660Abstract: The invention relates to a compound of formula (1)(A chemical formula should be inserted here—please see paper copy enclosed) wherein Q is —CO— or —C(R4)(R5)— (wherein R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group) and Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.Type: GrantFiled: July 16, 2002Date of Patent: April 22, 2008Assignee: AstraZeneca ABInventors: Rachel Heulwen Reynolds, Anthony Howard Ingall
-
Patent number: 7064126Abstract: The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO—G or SO2—G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof.Type: GrantFiled: January 15, 2004Date of Patent: June 20, 2006Assignee: AstraZeneca ABInventors: Martin Edward Cooper, Simon David Guile, Anthony Howard Ingall, Rukhsana Tasneem Rasul
-
Patent number: 6890923Abstract: A compound of formula or a pharmaceutically acceptable salt thereof, wherein R is —C(O)Ar1, —C(R4)(R5)Ar1 or Ar3; R3 represents a group X—R10 or Ar2; X represents a bond or a group NR11; and R10 represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted by one or more substituents independently selected from carboxyl, hydroxyl, —C(O)—R12, C3-6 cycloalkyl, morpholinyl, —NR13R14, —SR15, —OR16, phenyl and halophenyl, or R10 represents a C3-6 cycloalkylcarbonyl, —C(O)CH2CN, halophenylcarbonyl or trifluoromethylcarbonyl group. The compounds or compositions thereof are useful in the treatment or prophylaxis of autoimmune, inflammatory, proliferative and hyperproliferative diseases.Type: GrantFiled: December 16, 2002Date of Patent: May 10, 2005Assignee: AstraZeneca ABInventors: Anthony Howard Ingall, John Raymond Bantick, Matthew William Dampier Perry
-
Publication number: 20040254198Abstract: The invention relates to a compound of formula (1); wherein: R1 and R2 each independently represent a C1-6alkyl, C3-6 alkenyl, C3-6 cycloalkyl C1-3 alkyl or C3-6 cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R3 is isoxyzolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is CO— or C(R4)(R5)—(wherein R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group); Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.Type: ApplicationFiled: July 21, 2004Publication date: December 16, 2004Inventors: Rachel Heulwen Reynolds, Anthony Howard Ingall, Rukhsana Tasneem Rasul, Simon David Guile, Martin Edward Cooper
-
Publication number: 20040171623Abstract: The invention relates to a compound of formula (1)(A chemical formula should be inserted here—please see paper copy enclosed) wherein Q is —CO— or —C(R4)(R5)— (wherein R4 is a hydrogen atom or C1-4alkyl and R5 is a hydrogen atom or hydroxy group) and Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.Type: ApplicationFiled: January 8, 2004Publication date: September 2, 2004Inventors: Rachel Heulwen Reynolds, Anthony Howard Ingall
-
Publication number: 20040122028Abstract: The invention provides thieno[2,3-d]pyrimidinediones of general formula 1Type: ApplicationFiled: December 16, 2002Publication date: June 24, 2004Inventors: Anthony Howard Ingall, John Raymond Bantick, Matthew William Dampier Perry
-
Patent number: 6297232Abstract: The invention relates to triazolo[4,5-d]pyrimidin-3-yl derivatives which are useful in the treatment of platelet aggregation disorders.Type: GrantFiled: February 19, 1999Date of Patent: October 2, 2001Assignee: AstraZeneca ABInventors: Roger Victor Bonnert, Anthony Howard Ingall, Brian Springthorpe, Paul Andrew Willis